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Abstract
Background: Multidrug resistant-tuberculosis (MDR-TB) is a threat to global tuberculosis control which is worsened
by human immune-deficiency virus (HIV) co-infection. There is however paucity of data on the effects of antiretroviral
treatment (ART) before or after starting MDR-TB treatment. This study determined predictors of mortality and treatment
failure among HIV co-infected MDR-TB patients on ART.
Methods: A retrospective medical record review of 1200 HIV co-infected MDR-TB patients admitted at Sizwe Tropical
Disease Hospital, Johannesburg from 2007 to 2010 was performed. Chi-square test was used to determine treatment
outcomes in HIV co-infected MDR-TB patients on ART. Multivariable logistic regression and Poisson models were used
to determine predictors of mortality and treatment failure respectively.
Results: Mortality was higher (21.8 % vs. 15.4 %) among patients who started ART before initiating MDR-TB treatment
compared with patients initiated on ART after commencing MDR-TB treatment (p = 0.013). Factors significantly
associated with mortality included: the use of ART before starting MDR-TB treatment (OR 1.65, 95 % CI 1.02–2.73),
severely-underweight (OR 3.71, 95 % CI 1.89–7.29) and underweight (OR 2.35, 95 % CI 1.30–4.26), cavities on chest
x-rays at baseline (OR 1.76, 95 % CI 1.08–2.94), presence of other opportunistic infections (OR 1.80, 95 % CI 1.10–2.94)
and presence of other co-morbidities (OR 2.26, 95 % CI 1.20–4.21). Factors predicting failure were severe anaemia (IRR
(OR 4.72, 95 % CI 1.47–15), other co-morbidities (OR 2.39, 95 % CI 1.05–5.43) and modified individualised regimen at
baseline (OR 2.15, 95 % CI 0.98–4.71).
Conclusions: High mortality among patients already on ART before initiating MDR-TB treatment is a worrisome
development. Management of adverse-events, opportunistic infections and co-morbidities in these patients is
important if the protective benefits of being on ART are to be maximized. There is the need to intensify intervention
programmes targeted at early identification of MDR-TB, treatment initiation, drug monitoring and increasing adherence
among HIV co-infected MDR-TB patients.
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Background
Globally, about 480,000 incident Multidrug-Resistant
tuberculosis (MDR-TB) cases were diagnosed among
pulmonary TB (PTB) patients in 2013 [1], which is an
increase compared to the 450,000 cases reported in
2012 [2]. About 210 000 of the 1.5 million TB deaths
globally in 2013 were due to MDR-TB [1]; which is an
increase compared to 170,000 deaths of the 1.3 million TB
related deaths in 2012 [2]. South Africa is included as one
of the countries by the WHO to have over 80 % of the es-
timated MDR-TB cases worldwide [2].
MDR-TB poses a threat to global TB control pro-
grammes [3], and this is aggravated in resource limited
and low-income countries due to inadequate availability
of prompt diagnostic and treatment measures [4]. The
co-infection of MDR-TB and HIV has been described by
Wells et al. as the “Perfect storm” [5]. In South Africa
the MDR- and XDR-TB epidemic have mainly been
driven by the HIV epidemic and inadequate airborne in-
fection control measures [6]. The rapid spread of MDR-
TB among HIV-positive patients is due to the impaired
ability of the immune system to contain the MDR-TB
bacilli in these patients as this applies also to the nor-
mal TB bacilli [7]. The probability of developing TB
among people living with HIV is 29 times higher com-
pared to the probability of developing TB among HIV-
negative people [1].
Diagnosis and treatment of MDR-TB has been quite a
challenging venture around the globe especially in the
resource limited settings. This is even more difficult
among HIV-infected individuals as the classical symp-
toms of PTB may not be as pronounced as in HIV nega-
tive patients. Also HIV positive patients are sometimes
smear negative, hence presentations of TB amongst these
patients may be over-looked and attributed to the HIV in-
fection. Further difficulties in early diagnosis can be as-
cribed to delays in results of drug susceptibility testing
(the gold standard for diagnosis of MDR-TB) which is
sometimes not feasible at baseline for all patients. The ad-
verse events from lifelong treatment of HIV with anti-
retroviral therapy (ART) coupled with side effects from
MDR-TB drugs make the management and outcomes of
MDR-TB in co-infected patients very challenging [4].
Research work carried out on timing of ART initiation
in patients with pan susceptible TB used ARV-naïve TB
patients [8], without looking at the effect of ART initi-
ation before the start of TB treatment. There have been
few reported studies looking at the effect of timing of
initiation of ART on the outcomes of MDR-TB treat-
ment in a cohort of HIV positive patients [9–11], but
none in Sub-Saharan Africa (SSA). These studies did not
consider timing of ART based on before or after initi-
ation of MDR-TB treatment. A study done in SSA by
Satti H, et al. for both HIV infected and un-infected
patients during a sub-group analysis revealed no associ-
ation between being on ART prior to start of MDR-TB
treatment with increased hazard of treatment failure or
mortality, although the comparison group was the ART-
naïve patients [12].
Hence, data is highly needed in SSA on the effect of
timing of ART initiation before or after commencement
of MDR-TB treatment on MDR-TB outcomes in HIV
positive patients; in order to help evaluate the efficien-
cies/deficiencies of MDR-TB treatment and ART pro-
grammes. Therefore it is essential to ascertain the role
timing of introduction of ART plays in the management
of patients with MDR-TB and HIV co-infection. Such
findings could guide policy change so as to improve
MDR-TB treatment among HIV co-infected patients in
South Africa. The objectives of this study were to de-
scribe the clinical characteristics and outcomes of MDR-
TB treatment; and determine the predictors of mortality,
and treatment failure in HIV-TB co-infected patients




This was a retrospective review of medical records of
HIV positive MDR-TB adult patients who were regis-
tered into the South African National MDR-TB program
from 1st January 2007 to 31st December 2010 and receiv-
ing treatment at Sizwe Tropical Disease Hospital.
Study setting and study population
Sizwe Tropical Disease Hospital (STDH) is situated at
Edenvale and was established in 1895. In 2002, it became
a specialised Provincial centre for the treatment of MDR-
TB. In 2006, it was also mandated to treat XDR-TB fol-
lowing the emerging burden of DR-TB in South Africa.
The hospital serves a vast majority of referred MDR/XDR-
TB patients in Gauteng Province, who are treated as in-
and out-patients. The study population comprised all TB
patients aged 18 years and older registered for MDR-TB
treatment at STDH.
Study sample
A total of 1200 records of adult patients from the data-
base of STDH who were MDR-TB/HIV co-infected were
reviewed over a four year period. The following eligibil-
ity criteria were applied to ensure that the study sample
was correctly selected (Fig. 1). The inclusion criteria in-
cluded patients on treatment for MDR-TB who were:
HIV positive adults aged 18 years and older, with con-
firmed drug susceptibility test results showing resistance
to isoniazid and rifampicin. Patients younger than 18 years,
and those who were HIV negative, with unknown HIV
status or no HIV test results were excluded from the
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study. Additionally, those with missing case notes, or
whose DST was not confirmatory of MDR-TB, earlier
treatment dates before commencement of study, who
died within 24 h of commencement of MDR-TB treat-
ment and XDR-TB patients were also excluded from
the study.
Data sources and measurement
Culture positive and confirmed MDR-TB patients using
DST or line probe assay (LPA) in all the sub-divisions
of the National Health Laboratory Service (NHLS)
throughout Gauteng province were referred from their
clinics to Sizwe Tropical Disease Hospital. Patients
Fig. 1 Exclusion and inclusion criteria flowchart of the cohort
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were first screened at Gateway clinic to ensure that re-
sults were suggestive or confirmatory of MDR-TB before
registration into the National MDR-TB programme. This
was followed by a DST for all the first and second-line
anti-tuberculous agents. Baseline measurements of weight,
height, haemoglobin level, electrolytes, urea and creatin-
ine, thyroid function test, liver function test, CD4 cell
count, and audiometry were also done prior to or during
treatment.
Patients with unknown HIV status were referred to
Thusong clinic (a special clinic in STDH for HIV
management) for HIV counselling and testing. An ini-
tial rapid test was done and a reactive result necessi-
tated a confirmation with Architect Abbot (IL, USA)
Enzyme Linked Immuno-sorbent Assay (ELISA). Newly
diagnosed HIV patients were encouraged to initiate ART
as soon as possible except where patients were too ill to
commence treatment or declined initiation of ART. Prior
to 2010, the WHO guidelines for commencement of ART
in patients with a confirmed diagnosis of DR-TB was
based on a CD4 count of less than 350 cells/mm3.[13]
The guideline that followed regulated that patients start
ART within 2–8 weeks, irrespective of the CD4 cell
count [14, 15]. Patients’ ART status was also confirmed
by physicians on admission from the referral clinic or
by pill inspection. Patients diagnosed to be HIV positive
on admission and those already on ART were referred
to Thusong clinic for adherence counselling, continuous
ARV administration and follow-up on HIV treatment.
The majority of the patients started the standardized
MDR-TB regimen which utilises five drugs namely
Kanamycin/Amikacin (KM/AM), Moxifloxacin (MFX),
Ethionamide (ETO), Terizidone (TDR), Ethambutol (EMB)
and/or Pyrazinamide (PZA) taken at least six days a week
for at least 6 months during the intensive phase (IP),
followed by at least 18 months of MFX/ETO/PZA/TDR
after culture conversion for the continuation phase (CP)
[14]. The choice for the next regimen was individualized
based on follow-up DST results. Some patient’s regimen
were modified at baseline (called individualised regimen
at baseline in this study) following the advent of pre-
existing serious adverse events, co-morbidities such as
diabetes, pre-existing psychosis and the presence of
pre-XDR strains (resistance to first line anti-TB agents,
and to either one of the two key second line injectable
or the flouroquinolone drugs, but not classified as
XDR-TB). Most of the patients were transferred to their
local clinics with DOTS support groups who continued
monitoring patients’ treatment after one or two con-
secutive negative culture results.
Adverse events such as ototoxicity, nephrotoxicity, hep-
atotoxicity, joint pains, gastro-intestinal symptoms like nau-
sea and vomiting requiring treatment, visual changes and
conjunctivitis, psychosis, depression, peripheral neuropathy,
hyperuricemia, hypothyroidism and gynaecomastia were
reviewed and managed. Patients were evaluated for co-
morbidities such as diabetes mellitus (DM), hypertension,
cerebrovascular disease, heart failure, cardiomyopathies,
and arrhythmias, asthma and chronic obstructive airway
disease, chronic kidney disease, chronic liver disease, pan-
creatic disorders, deep venous thrombosis and cancers. The
presence of opportunistic infections (candidiasis, recur-
rent oral or genital Herpes simplex virus (HSV) infec-
tion, Pneumocystis Jiroveci Pneumonia (PJP), Herpes
zoster infection, Cryptococcal infection, Cytomegalo-
virus infection, cervical dysplasia or cancer, Kaposi sar-
coma and HIV-associated nephropathy (HIVAN)) were
managed and documented by clinicians during treat-
ment and follow-up.
Follow-up included: visits one month after discharge
and subsequently 3 monthly with chest X-rays reviewed
during each visit until the patient had completed treat-
ment except where patients had other co-morbidities.
Upon completion of treatment, patients were followed
up every 6 months for 2 years. Outcomes of MDR-TB
treatment included cure, completed treatment, defaulted,
failed treatment, transferred out, still on treatment and
died [14, 16]. “ART prior” to MDR-TB treatment was
defined as patients having been on ART before com-
mencing MDR-TB treatment while “ART after” was de-
fined as patients initiated on ARVs after initiating MDR-
TB treatment but before ascertainment of MDR-TB
treatment outcome.
Data collection
Part of the data for this study comprised demographic
and outcome records from the National TB registers.
The medical case files of HIV positive patients were
reviewed for socio-demographic and clinical information
not recorded on the TB register. Baseline x-rays of the
patients were also reviewed. Data were entered into an
Excel spreadsheet. Inconsistencies were verified from
case records and errors were corrected. Data collection
started on the 14th November, 2013 and ended on the
21st February, 2014.
Data analysis
Data were transferred from the Excel spread sheets into
STATA version 12.0 for analysis. The data were cleaned
by excluding individual records that did not meet the
eligibility criteria (Fig. 1); and missing data were checked
for each variable. Pearson’s chi-square test was used to
compare categorical variables across the main exposure
groups (receiving ART before or after commencing
MDR-TB treatment) and Fisher’s exact test was used
where there were sparse data of ≤5 in 20 % of the cells.
Continuous variables which followed a normal distribu-
tion were compared using the student t-test and the
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Wilcoxon Rank-sum test was used for non-normal/
skewed data. All analyses were performed after excluding
missing data.
Multivariable logistic regression models were used to
assess the effect of timing of ART and other predictors
of mortality; while multivariable Poisson models were
used to determine the predictors of treatment failure
due to the low prevalence of failure compared to the
total sample size. Potential confounders were adjusted
for in the final multivariable models. Odds ratios were
calculated for logistic regression models and incidence
rate ratios (IRR) for Poisson regression models at 95 %
confidence interval and alpha level of <0.05. Twelve pa-
tients who started ART one week prior to commence-
ment of MDR-TB treatment were excluded from the
multivariable logistic regression analysis to avoid dilu-
tional effect due to insufficient time for occurrence of a
significant therapeutic effect of ART among this group
of patients.
Ethical considerations
The study was approved by the University of the
Witwatersrand Human Research Ethics Committee
(Medical) in 2013. Ethics approval number M130961.
Results
Baseline characteristics
A total of 2005 MDR-TB patients were admitted from 1st
January, 2007 to 31st December, 2010. Of these, 1200
adult patients had HIV positive status recorded on the
database out of which 253 patients were excluded from
the study. Of the 253 individuals excluded, 31 had missing
case notes, 12 were confirmed HIV negative, 2 had un-
known HIV status, 173 were not on ART, while the ART
status of 17 of them could not be determined. Addition-
ally, 7 patients were misdiagnosed as MDR-TB (mono/
poly resistance), 3 had earlier treatment start dates, 3 died
within 24 h of starting treatment, and two defaulted/
died after the first visit. One patient with XDR-TB and
an infant were also excluded. Therefore 947 patients
who were on ART met the eligibility criteria (Fig. 1).
A higher proportion of patients 57.5 % (545) were on
ART prior to commencing MDR-TB treatment, whereas
42.5 % (402) commenced ART after initiating MDR-TB
treatment. The median duration for initiation of ART
was 218 days (IQR = 70–570) for patients on ART prior
to commencement of MDR-TB treatment and 58 days
(IQR = 32–112) for patients initiated on ART after com-
mencing MDR-TB treatment. Of the 545 patients on
ART prior to initiating MDR-TB treatment, 12 were
commenced on ART one week before the start of
MDR-TB treatment and were further excluded from the
final multivariable analysis. Extra-pulmonary (EPTB)/
PTB was significantly higher among patients who
commenced ART before compared with those who
started ART after MDR-TB treatment initiation (20.7 %
vs. 13.9 %, (p = 0.007)). The median time from the start
of MDR-TB treatment to mortality was shorter for pa-
tients on ART prior to starting MDR-TB treatment
139 days (IQR = 33–411) compared to 321 (IQR = 105–
599) for patients initiated on ART after commencing
MDR-TB treatment (Table 1).
Outcomes of MDR-TB by ART treatment groups
Treatment outcomes were not significantly different be-
tween patients on ART before and after the commence-
ment of MDR-TB treatment (p = 0.096) (Table 2).
When the analysis was restricted to patients who died,
the proportion of mortality was higher for those on
ART prior to beginning MDR-TB treatment (21.8 % vs.
15.4 %, (p = 0.013)) Table 2.
Pattern of co-morbidities among HIV co-infected MDR-TB
patients
For patients with the presence of other co-morbidities,
severe sepsis was the highest 18.1 %, followed by hyper-
tension (11.2 %), and diabetes (9.4 %). The proportion of
patients with cerebrovascular diseases, deep venous
thrombosis and epilepsy were similar; just over 8.0 %
each. Congestive cardiac failure and chronic obstructive
airway diseases made up over 13 % of the co-morbidities
(Table 3).
Predictors of mortality
Patients who received ART prior to commencing
MDR-TB treatment were 1.7 times more likely to die
compared with those who commenced ART after initi-
ation of MDR-TB treatment (OR 1.65, 95 % CI 1.02–
2.73, p = 0.050), adjusting for confounders such as BMI,
haemoglobin, CD4 cell count and the presence of other
opportunistic infections. Compared with normal BMI,
those who were severely underweight (OR 3.71, 95 %
CI 1.89–7.29, p <0.001) and underweight (OR 2.35,
95 % CI 1.30–4.26, p = 0.005) were more likely to die.
Patients with the presence of cavitary lesions on base-
line chest x-ray were 1.8 times more likely to die (OR
1.76, 95 % CI 1.08–2.85, p = 0.023) compared with pa-
tients without cavitary lesions. The presence of other
opportunistic infections was associated with a higher odds
of mortality compared with patients without other oppor-
tunistic infections (OR 1.80, 95 % CI 1.10–2.94, p = 0.019).
Compared with patients without co-morbidity, individuals
with co-morbidities were 2.3 times more likely to die (OR
2.26 95 % CI 1.20–4.27, p = 0.012) (Table 4).
Predictors of treatment failure
Patients with severe anaemia had nearly 4.7 times higher
rate of failure compared with patients with normal
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Table 1 Baseline characteristics of MDR-TB/HIV co-infected adults based on exposure to ART before/after the commencement of
MDR-TB treatment
Factors ART Prior ART After p-value
N (%) (N = 545) N (%) (N = 402)
Age 36 (31–43)* 35.5 (31–42)* 0.557b
Sex
Male 264 (48.4) 193 (48.0) 0.896c
Female 281 (51.6) 209 (52.0)
Categories of MDR-TB
Category I (New) 107 (19.6) 107 (26.6) 0.026*c
Category II 438 (80.4) 295 (73.4)
Pre-treatment smear status
Negative 166 (30.5) 134 (33.3) 0.595b
Positive 317 (58.2) 221 (55.0)
Not available 62 (11.4) 47 (11.7)
Site of TB
Pulmonary 432 (79.3) 346 (86.1) 0.007*c
Extra-Pulmonary + Pulmonary 113 (20.7) 56 (13.9)
BMI categories (Kg/m2)
Severely Underweight (<16) 68 (15.4) 41 (11.4) 0.174c
Underweight (≥16–18.49) 130 (29.4) 111 (31.0)
Normal (≥18.5–24.99) 195 (44.1) 176 (49.2)
Overweight/ obese (25–29.99) 49 (11.1) 30 (8.4)
Co-trimoxazole Prophylaxis
No 21 (4.4) 32 (9.7) 0.003*c
Yes 459 (95.6) 297(90.3)
CD4 cell count (mls/mm3) 160.5 (89–270)a 156 (66–257)a 0.1906b
CD4 Categories (mls/mm3)
<150 241 (46.5) 187 (48.1) 0.296c
150–349 209 (40.4) 140 (36.0)
≥350 68 (13.1) 62 (15.9)
Haemoglobin (g/dl) 11.3 (2.4)* 10.8(2.2)* 0.0012*d
Haemoglobin (g/dl)
Severe Anaemia (<7.0) 24 (4.5) 13 (3.3) 0.009*c
Moderate Anaemia (7.0–9.9) 120 (22.3) 123 (31.0)
Mild Anaemia (10–10.99) 85 (15.8) 70 (17.7)
Normal (≥11) 308 (57.4) 190 (48.0)
Duration on ART 218 (70–570)b 57.5 (32–111.5)b
Outcome duration or Person time (days) 251 (90–725)b 720 (330–945)b 0.0286*b
Treatment-initiation-delay 11 (5–22)b 10 (6–21)b 0.921b
Infiltrative changes on x-ray
No 24 (4.5) 11 (2.8) 0.179c
Yes 513 (95.5) 385 (97.2)
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haemoglobin level (OR 4.72, 95 % CI 1.47–15.08, p =
0.009). The presence of other co-morbidities was associ-
ated with a 2.4 times higher rate of failure compared
with those without other co-morbidities (OR 2.39, 95 %
CI 1.05–5.43, p = 0.039). Patients on modified individua-
lised regimen at baseline had a 2 times higher rate of
failure compared with patients on standardized regimen
at baseline (OR 2.15 95 % CI 0.98–4.71, p = 0.056), as
observed in Table 5.
Discussion
The study aimed at ascertaining the clinical charac-
teristics and outcomes of MDR-TB in HIV co-
infected patients based on timing of ART initiation,
as well as determining the predictors of mortality,
and treatment failure. This study revealed a higher
proportion of new MDR-TB cases and the presence
of other non-TB opportunistic infections among pa-
tients who initiated ART after commencing MDR-
TB. These findings point to the importance of early
initiation of ARVs and its protective benefits for
HIV positive patients. On the whole, outcomes of
MDR-TB did not differ significantly between patients
who started ART before or after initiation of MDR-
TB except for mortality which was higher among pa-
tients who commenced ART before initiating MDR-
TB treatment. Risk factors for mortality were the use
of ART before the commencement of MDR-TB, be-
ing severely underweight and underweight, cavitary
lesions on baseline chest x-ray, the presence of other
opportunistic infections and other co-morbidities.
Severe anaemia at baseline, and the presence of
other co-morbidities were associated with higher
rates of treatment failure.
Predictors of mortality
Antiretroviral therapy use prior to MDR-TB treatment
initiation was significantly associated with higher odds
of mortality compared with ART initiation after com-
mencement of MDR-TB treatment. This finding is sur-
prising and has not been reported before by other
studies. It should be assumed that patients should have
benefited from being on ARVs before MDR-TB treat-
ment. Based on this data, a greater percentage of pa-
tients who commenced ART before MDR-TB treatment
initiation were severely underweight. They also had
more extra-pulmonary TB, adverse events, and modified
regimen based on patients’ history at baseline compared
Table 1 Baseline characteristics of MDR-TB/HIV co-infected adults based on exposure to ART before/after the commencement of
MDR-TB treatment (Continued)
Cavitary change on x-ray
No 315 (58.7) 237 (59.8) 0.715b
Yes 222 (41.3) 159 (40.2)
Fibrotic changes on x-ray
No 77 (14.3) 58 (14.7) 0.883c
Yes 460 (85.7) 337 (85.3)
Other Opportunistic Infections
No 399 (73.4) 228 (57.1) <0.001*c
Yes 145 (26.6) 171 (42.9)
Comorbidity
No 461 (85.8) 345 (88.0) 0.337c
Yes 76 (14.2) 47 (12.0)
Adverse events
No 295 (54.8) 239 (61.1) 0.055c
Yes 243 (45.2) 152 (38.9)
Regimen type at baseline
Standardised 370 (68.5) 295 (75.1) 0.029*c
Modified individualised 170 (31.5) 98 (24.9)
Treatment-initiation-delay: Duration from report of MDR-TB to initiation of treatment
N - Total number in each group; % - Column percentages; Numbers may not add-up to total because of missing variables
Test statistic based on bRank-sum test, cChi-square test and dt-test
*Significant p < 0.05, Mean and Standard Deviation. aMedian and Inter-quartile ranges
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with patients who started ART after initiation of MDR-
TB treatment at baseline. A lack of effect of ART from
poor adherence, and treatment failure may have been re-
sponsible for this trend. The availability of viral load data
at baseline would have further buttressed this fact, but
this was not done routinely during the study period.
Prior to 2010, MDR-TB patients were initiated on ARTs
if their CD4 cell count was <350 cell/mm3 based on the
WHO guidelines [13]. Thereafter, ART was encouraged to
be initiated within 6–8 weeks of starting MDR-TB treat-
ment irrespective of CD4 count [15]; hence prior to 2010,
patients with higher CD4 cell count were monitored until
their CD4 counts dropped to <350 cells/mm3. This trend
also explains the presence of more EPTB and the slightly
lower baseline weight and the mortality seen in this group.
Following prior initiation of ART, their CD4 cell counts
may have improved such that they appeared similar CD4
cell count as with patients who started on ART after initi-
ating MDR-TB treatment at baseline, as noted in our
study.
This result poses questions on the issue of adherence
to ART for patients who were already on ART prior to
MDR-TB treatment in a country like South Africa with
majority of HIV positive patients on ARVs. Additionally,
drug-drug interactions between the MDR-TB and ARVs
pills may have resulted in the high mortality in this
study. IRIS was considered as the most potential explan-
ation for this finding simply due to the fact that when
analysis was restricted to patients who were on ART
within six months as opposed to 3 months prior to com-
mencement of MDR-TB treatment compared with those
who started on ART after initiating MDR-TB treatment,
no statistically significant relationship was observed with
prior ART initiation and mortality. This further affirms
the rigorous monitoring and management of IRIS by at-
tending clinicians. Clinicians should not undervalue the
role of adherence to ART treatment in patients who are
already on ART before starting MDR-TB treatment. Ap-
propriate management of already existing adverse events,
opportunistic infections and co-morbidities in these pa-
tients are important to maximise the protective benefits of
being on ART before initiating MDR-TB treatment, and
on the whole achieve better treatment outcomes.
This study found that being severely underweight and
underweight were risk factors of mortality. These find-
ings are similar to previous studies [9, 12, 17–19]. HIV
and TB are linked to malnutrition [18]; and wasting syn-
drome is a hallmark of severity of TB and HIV infection,
therefore its strong association as a predictor of mortal-
ity irrespective of patients’ ART status is not surprising.
A Cavitary lesion seen on chest x-ray at baseline was a
risk factor of mortality. There have been conflicting
studies on the role of cavitation on chest x-ray as a risk
factor of poor outcomes. Some studies have linked the
presence of cavitation on chest x-rays with longer cul-
ture conversion time; a surrogate marker for poor out-
comes [20–22]. Others have found no statistically
significant relationship between cavitation and poor out-
comes [17, 23]. In a recent study done by Brust JC et al.
in South Africa, its failure of finding a significant
Table 3 Pattern of co-morbidities among HIV co-infected




Congestive heart failure 11 (6.9)
Kidney diseases 12 (7.5)
Cerebrovascular diseases 13 (8.1)
Epilepsy 13 (8.1)
Severe sepsis 29 (18.1)
DVT 14 (8.8)
COADs 10 (6.2)
Chronic liver Disease 3 (1.9)
Cancers 2 (1.3)
Others 20 (12.5)
N: Total number in each group; %: percentage in each category
DVT Deep venous thrombosis
COAD Chronic obstructive airway diseases
Table 2 Outcomes of MDR-TB in HIV co-infected adults based
on commencement of ART prior to or after MDR-TB treatment
initiation
Factors ART Prior ART After p-value
N (%) N (%)
Final Outcomes
Still on treatment 5 (0.9) 8 (2.0) 0.096
Transferred out 26 (4.8) 18 (4.5)
Treatment Defaulted 105 (19.3) 101 (25.1)
Treatment Completed 92 (16.9) 71 (17.7)
Cure 182 (33.4) 130 (32.3)
Failure 16 (2.9) 12 (3.0)
Died 119 (21.8) 62 (15.4)
Died
No 426 (78.2) 340 (84.6) 0.013*
Yes 119 (21.8) 62 (15.4)
Failure
No 529 (97.1) 390 (97.0) 0.965
Yes 16 (2.9) 12 (3.0)
Total 545 402
N - Total number in each group
% - Column percentages
*Significant p < 0.05
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Table 4 Predictors of mortality in HIV-positive adults on MDR-TB treatment at Sizwe Tropical Disease Hospital, Johannesburg
aUnivariable Analysis bMultivariable Analysis
Factor OR (95 % CI) p-value OR (95 % CI) p-value
ART regimen
After 1.00 1.00
Prior 1.49 (1.06–2.09) 0.021* 1.65 (1.00–2.73) 0.050*
Age 1.01 (0.99–1.03) 0.481
Sex
Female 1.00 1.00
Male 1.08 (0.78–1.49) 0.661 1.58 (0.94–2.66) 0.085
Site of TB
Pulmonary 1.00
Extra-Pulmonary + Pulmonary 1.40 (0.94–2.09) 0.098
BMI categories (kg/m2)
Severely Underweight (<16) 4.61 (2.77–7.68) <0.001* 3.71 (1.89–7.29) <0.001*
Underweight (≥16–18.49) 2.33 (1.49–3.65) <0.001* 2.35 (1.30–4.26) 0.005*
Normal (≥18.5–24.99) 1.00 1.00
Overweight/ obese (25–29.99) 1.20 (0.57–2.51) 0.630 2.30 (0.92–5.71) 0.074
Co-trimoxazole Prophylaxis
No 1.00 1.00
Yes 1.33 (0.62–2.89) 0.464 1.30 (0.47–3.54) 0.613
CD4 Categories (mls/mm3)
<150 2.88 (1.62–5.14) <0.001* 1.56 (0.73–3.38) 0.243
150–349 0.91 (0.48–1.72) 0.770 0.63 (0.28–1.42) 0.266
≥350 1.00 1.00
Haemoglobin (g/dl) 0.76 (0.70–0.82) <0.001* 0.90 (0.79–1.02) 0.090
Infiltrative changes on x-ray
No 1.00
Yes 0.74 (0.33–1.67) 0.470
Cavitary changes on x-ray
No 1.00 1.00
Yes 1.25 (0.89–1.74) 0.191 1.76 (1.08–2.85) 0.023*
Fibrotic changes on x-ray
No 1.00
Yes 1.17 (0.71–1.91) 0.527
Other Opportunistic Infections
No 1.00 1.00
Yes 2.54 (1.82–3.55) <0.001* 1.80 (1.10–2.94) 0.019*
Comorbidity
No 1.00 1.00
Yes 3.97 (2.64–5.97) <0.001* 2.26 (1.20–4.27) 0.012*
Adverse events
No 1.00 1.00
Yes 1.45 (1.04–2.02) 0.028* 1.09 (0.68–1.77) 0.720
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relationship between cavitation and longer time to spu-
tum conversion may have been due to the limited sam-
ple size of 56 patients [23].
The presence of other non-TB opportunistic infections
was a significant predictor of mortality. This finding has not
been reported before by other studies beyond the descriptive
level [9]. There is a higher risk of mortality and development
of other opportunistic infections in HIV-TB co-infected pa-
tients [24, 25]. The role of other non-TB opportunistic infec-
tions is important in the clinical and prognostic staging of
HIV positive patients. Serious opportunistic infections like
Kaposi sarcoma, cervical cancer, Cytomegalovirus (CMV) in-
fections, HIV-associated nephropathy (HIVAN), etc. are
already indicators of the depressed immunity with an in-
crease likelihood of mortality masking the importance of
timing of ART initiation in these patients.
In this study the presence of co-morbidities was a sig-
nificant risk factor of mortality. This result was re-
ported in a recent study in the United Kingdom and
Peru [26, 27]. However, the proportion of co-morbidities
like diabetes, chronic kidney disease, and chronic liver dis-
ease was higher than that reported in the United King-
dom. There is an established “bidirectional synergistic”
relationship between TB-HIV co-infection and the devel-
opment of co-morbidities like DM [28–30]. Treatment of
HIV with ART especially with the protease inhibitors is
associated with hyperglycaemia, insulin resistance, dys-
lipidaemia [31]; not only leading to the development
and complication of DM, but cardio-vascular, cerebro-
vascular, hepatic and renal problems. Most studies done
on the role of certain co-morbidities on TB mortality
focus on single disease entity like DM; with positive
[32], and negative [17] results. This study is the first in
South Africa to incorporate the presence of other non-
communicable co-morbidities apart from DM to assess
its impact on mortality in MDR-TB HIV co-infected pa-
tients, especially with the emerging link of infectious
and non-communicable diseases.
Predictors of treatment failure
Severe anaemia (haemoglobin <7.0 mg/dl) at baseline
predicted treatment failure. The causes of anaemia in
MDR-TB HIV co-infected patients are multi-factorial;
resulting from the HIV/mycobacterial infection and
treatment with both anti-TB and ARV medications. This
finding is consistent with that of Mitnick C, et al. where
low haematocrit was associated with about 4 times in-
crease in the hazard of failure or death compared with
normal haematocrit [18].
This study found that the presence of other co-
morbidities was associated with a higher rate of treat-
ment failure. The co-existence of other communicable
and chronic non-communicable medical conditions such
as DM, heart failure, cerebrovascular diseases, renal dis-
eases, etc. increases the pill burden, adverse events and
drug-drug interactions for HIV co-infected MDR-TB
treatment. These patients require regimen modifications
based on their clinical state, and hence may affect ad-
herence to both ART and MDR-TB treatment, and lead
to treatment failure. DM has been associated with
MDR-TB [33] and PTB [34] treatment failure; however
these studies did not consider the effect of other co-
morbidities.
Modified individualised regimen at baseline for patients
based on co-morbidities and adverse-events was signifi-
cantly associated with treatment failure. The treatment of
MDR-TB utilizes at least five medications at baseline and
the WHO advocates the use of DST results to guide
treatment regimen. In the practical clinical setting the
presence of severe adverse-events, co-morbidities, and
pre-XDR strains guide the clinicians on what regimen
to use in initiating MDR-TB treatment regimen not just
the DST result. Therefore for some of these patients
certain drugs were delayed or added (in cases of pre-
XDR strains) at baseline pending improvement in clin-
ical condition. For example, Kanamycin/Amikacin were
omitted and substituted with other drugs when there
was renal toxicity. Terizidone was substituted if there
was a serious psychiatric side effect. In cases of pre-
XDR TB, the deviation was solely based on available
antibiogram showing resistance to the injectable or Fluro-
quinolone. These patients termed as those on “modified
individualized regimen” in this study to reflect the chal-
lenges clinicians face when initiating MDR-TB treatment
using DST results bearing in mind patient centred care.
This finding supports the result by Leimane V et al. which
noticed that patients on ≤ 5 drugs for 3 months or more
were more likely to fail or die [19].
Table 4 Predictors of mortality in HIV-positive adults on MDR-TB treatment at Sizwe Tropical Disease Hospital, Johannesburg
(Continued)
Regimen type at baseline
Standardised 1.00
Modified individualised 1.55 (1.10–2.19) 0.013*
OR Odds ratio, 95 % CI (Confidence interval)
aUnadjusted model
bAdjusted for BMI, haemoglobin, CD4, and other opportunistic infections
*Significant p <0.05
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Limitations and strengths
This study depended on already collected data from
medical records, hence may not have measured all the
possible confounders. Viral load for patients would have
been a true test of adherence especially for patients on
ART prior to initiating MDR-TB treatment, thereby
helping in the explanation of the relevant findings. How-
ever, viral load could not be used as the definition of
virological suppression varied over the years according
to the NHLS definitions. Additionally only few data were
collected for this variable because during this period
viral load was expensive and could not be afforded for
all patients at baseline except where patients were sus-
pected to have had immunological or clinical failure.
In this study, timing of ART was stratified as before or
after commencement of MDR-TB treatment and this may
not have allowed proper assessment of the true effect of
duration of ART on the outcomes. Information on base-
line ART regimen were not collected, which would have
been a pointer to drug resistance and virological failure
and may have possibly helped in explaining the role of
timing of ART on mortality in terms of adverse-events
and toxicity of individual drugs. Coding co-morbidities as
a yes or no variable instead of looking at individual
Table 5 Predictors of treatment failure in HIV-positive adults on MDR-TB treatment at Sizwe Tropical Disease Hospital, Johannesburg
aUnivariable Analysis bMultivariable Analysis
Factor IRR (95 % CI) p-value IRR (95 % CI) p-value
ART regimen
After 1.00 1.00
Prior 1.01 (0.47–2.15) 0.988 0.80 (0.35–1.84) 0.606
Age groups
18–45 1.00
46–76 0.79 (0.27–2.28) 0.662
BMI 0.97 (0.87–1.07) 0.547 1.01 (0.94–1.09) 0.766
Haemoglobin (g/dl)
Severe Anaemia (<7.0) 2.69 (0.78–9.30) 0.117 4.72 (1.47–15.08) 0.009*
Moderate Anaemia (7.0–9.99) 1.09 (0.46–2.57) 0.839 0.97 (0.40–2.34) 0.944
Mild Anaemia (10–10.99) 0.43 (0.10–1.87) 0.260 0.25 (0.03–1.82) 0.172
Normal (≥11) 1.00 1.00
Infiltrative changes
No 1.00
Yes 1.01 (0.14–7.47) 0.990
Cavitary changes
No 1.00 1.00
Yes 1.81 (0.85–3.87) 0.125 2.14 (0.96–4.78) 0.064
Fibrotic changes
No 1.00
Yes 1.36 (0.41–4.50) 0.620
Comorbidity
No 1.00 1.00
Yes 1.79 (0.72–4.41) 0.207 2.39 (1.05–5.43) 0.039*
Adverse events
No 1.00 1.00
Yes 0.54 (0.24–1.23) 0.142 0.48 (0.21–1.09) 0.080
Regimen type at baseline
Standardised 1.00 1.00
Modified individualised 2.48 (1.18–5.20) 0.016* 2.15 (0.98–4.71) 0.056
IRR Incidence rate ratio
aUnadjusted models
bAdjusted for Co-trimoxazole prophylaxis, BMI and categories of MDR-TB
*Significant p <0.05
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diseases may have overestimated the effect of such vari-
able on the outcomes in patients who had one or two co-
morbidities compared to those who had a combination of
highly fatal co-morbidities. Findings of this study may not
be generalizable to regions with low ART coverage.
This is one of the largest cohorts of MDR-TB HIV co-
infected patients, allowing reasonable power to detect a
difference between the two exposure groups in relation
to the major outcomes and other risk factors for mortal-
ity, and failure. The objective measurements of the out-
comes minimised misclassification bias as majority of
patients were confirmed as cured or failed treatment
based on TB culture results from NHLS and extensive
follow-up. Mortality was also confirmed in the hospital
and for patients who died at home, regular tracing and
reminders for visits helped in ascertaining home-related
mortality. Certain variables like weight, height, CD4 count,
haemoglobin, and chest x-rays were collected within spe-
cified periods to prevent disparate exposure duration
hence, preventing over or under-estimation of the effect
size. Information on certain exposures like other oppor-
tunistic infections, co-morbidity and adverse events were
collected and this may have helped explain the predictors
of mortality, and failure. The standard practice of ascer-
taining patients’ART status at baseline and documentation
of definite start dates by physicians at Sizwe Hospital re-
duced the likelihood of misclassification bias based on
ART status.
Conclusions
This study provides new information while also reinfor-
cing old knowledge to clinicians and public health prac-
titioners for the identification of TB populations at
higher risk of death, and treatment failure. Mortality was
higher in patients on ART prior to start of MDR-TB
treatment compared with those initiated on ART after
commencing MDR-TB treatment. Strict adherence to
ART and monitoring for drug-drug interactions, man-
agement of adverse-events and existing co-morbidities
in HIV positive patients irrespective of their TB status is
pivotal to achieving favourable outcomes. The study re-
sults also places an emphasis on the role of Public health
practitioners to intensify intervention programmes tar-
geted at early screening and identification of MDR-TB,
treatment initiation, increasing adherence and drug
monitoring for HIV infected patients.
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